The hub has also been created to strengthen an existing relationship between Harvard and Roche that has been in place for over a decade.
Swiss pharmaceutical company Roche announced Friday it will open an innovation center in the Harvard University Enterprise ...
The Mayo Clinic estimates that menopause symptoms lead to $1.8 billion in lost work time per year in the U.S. About 5% of ...
TNKase — tenecteplase — is the first FDA-approved stroke medicine in nearly 30 years, offering a faster, simpler five-second ...
Roche and its Genentech subsidiary are planning to hitch up their cardiovascular, renal and metabolism R&D work and shift it ...
The U.S. Food and Drug Administration has approved TNKase (tenecteplase), a thrombolytic or clot-dissolving agent, for the ...
Genentech, a Roche Group company(OTCQX:RHHBY) said on Wednesday that the U.S. FDA accepted the company’s supplemental ...
The U.S. Food and Drug Administration (FDA) has accepted Genentech’s Supplemental Biologics License Application (sBLA) for ...
Genentech, a member of Roche (RHHBY), announced that the FDA has accepted the company’s supplemental biologics license application for Gazyva ...
In people with lupus nephritis, Gazyva demonstrated a complete renal response benefit, a meaningful clinical outcome linked to preservation of kidney function, and slowing or prevention of end-stage ...
Pharmaceutical Technology on MSN5d
Genentech wins FDA approval for second stroke treatmentGenentech’s label expansion for TNKase consolidates its market position for pharmacological stroke treatments.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback